Is AOD-9604 Legal in California? How to Access It Legally

What Is AOD-9604 and Why Does Its Legal Status Matter?

AOD-9604 is a synthetic peptide representing the C-terminal fragment of human growth hormone, specifically amino acids 176 through 191. Metabolic Pharmaceuticals developed it in the early 2000s with the hypothesis that this fragment drives the lipolytic activity of growth hormone without the insulin-desensitizing effects of the full hGH molecule. Because it is a fragment of a naturally occurring hormone, its regulatory classification is more complicated than a simple new chemical entity would be.

Legal status matters for a simple reason: if you receive AOD-9604 through an unlicensed vendor, a "research chemical" supplier, or an overseas pharmacy, you are accepting a product that has not been verified for sterility, potency, or identity. The FDA's adverse event reporting system contains cases involving contaminated compounded peptides, which is part of why the agency began tightening oversight of bulk peptide substances after 2020. [1]

How AOD-9604 Works

The peptide binds to beta-3 adrenergic receptors in adipose tissue, stimulating fat breakdown without activating IGF-1 pathways. In animal models published in the peer-reviewed literature, the fragment showed statistically significant reductions in body fat compared to saline controls. [2] Human trial data from Metabolic Pharmaceuticals' Phase 2 and Phase 3 programs (conducted between 2001 and 2004) demonstrated modest weight-loss signals, but the sponsor did not file a New Drug Application with the FDA, so the compound never completed the approval pathway.

Why Patients Are Asking About It Now

Telehealth expansion after 2020, combined with growing interest in GLP-1 receptor agonists and peptide therapies for body composition, pushed AOD-9604 back into patient searches. Clinics marketing "peptide protocols" began listing it alongside BPC-157, CJC-1295, and ipamorelin. That marketing surge attracted FDA attention, which is precisely how AOD-9604 ended up on the agency's 2023 bulk substance review list.

The Federal Regulatory Framework: FDA's Position on AOD-9604

The FDA regulates drugs and compounded preparations under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Compounding pharmacies operate under Sections 503A and 503B of that Act, as amended by the Drug Quality and Security Act of 2013. [3]

What the FDA's Bulk Substances List Actually Means

When the FDA places a substance on its "Category 2" list, it means the agency has received a nomination for that substance to be used in compounding but has not yet determined that it is appropriate for inclusion on the "Category 1" (positive) list. Category 2 status is not a ban. It means the FDA is actively evaluating the substance and that compounding from it remains in a legal gray zone while the review proceeds.

AOD-9604 was nominated as a 503A bulk drug substance. The FDA published its Category 2 designation in the context of ongoing review. [4] During this review period, a 503A pharmacy that compounds AOD-9604 is operating without clear federal authorization, which means the prescribing physician and the pharmacy share regulatory risk. The Pharmacy Compounding Advisory Committee (PCAC) evaluates factors including whether there is a clinical need not met by an approved drug and whether the substance's safety and effectiveness have been demonstrated.

503A vs. 503B: The Critical Distinction

503A pharmacies compound preparations for individual patients pursuant to a valid prescription from a licensed practitioner. They are regulated primarily by state boards of pharmacy. A 503A pharmacy in California, licensed by the California State Board of Pharmacy, may compound AOD-9604 for an individual patient if it determines that doing so is consistent with its own legal risk assessment and the prescriber has provided a valid prescription.

503B outsourcing facilities compound in larger batches without patient-specific prescriptions and distribute to healthcare providers. 503B facilities must use only bulk substances on the FDA-approved 503B bulks list. AOD-9604 is not on that list. A 503B facility cannot legally produce AOD-9604. [3]

This distinction explains why patients sometimes receive vials labeled "for research use only" from suppliers who are not registered as either 503A or 503B entities. Those products fall entirely outside the compounding pharmacy framework and are not legal for human use.

California State Law: What the CDPH and Board of Pharmacy Add (or Don't)

California does not have a state-specific statute that independently bans or authorizes AOD-9604. The California Department of Public Health (CDPH) and the California State Board of Pharmacy both defer to the federal FDA framework for compounded drug substances. [5]

California's Medical Practice Act and Off-Label Prescribing

Under the Medical Practice Act (California Business and Professions Code Section 2052 et seq.), a licensed California physician (MD or DO), nurse practitioner with prescriptive authority, or physician assistant with a valid prescribing agreement may prescribe any lawful medication for an off-label indication if, in their professional judgment, it is medically appropriate for the individual patient. This is the same legal basis used for off-label prescribing of any FDA-approved drug.

The legal complexity with AOD-9604 is that it is not an approved drug at all. Prescribing an unapproved compound is not categorically prohibited under the Medical Practice Act, but the prescriber takes on responsibility for demonstrating medical necessity and for ensuring the preparation comes from a licensed pharmacy. The Medical Board of California has not issued specific guidance on AOD-9604 as of this writing.

California Board of Pharmacy Oversight

The California State Board of Pharmacy licenses 503A compounding pharmacies operating within California and enforces state sterile compounding standards that in some cases exceed federal USP 797 and USP 800 requirements. [5] A California-licensed 503A pharmacy that elects to compound AOD-9604 must comply with those state sterile compounding regulations, maintain appropriate beyond-use dating, and produce the preparation under the order of a licensed prescriber for an identified individual patient.

No California Board of Pharmacy guidance specifically restricts AOD-9604, but the board has issued general guidance reminding pharmacies that compounding a substance from FDA's Category 2 list carries regulatory risk and that the pharmacist-in-charge bears professional responsibility for that decision.

How to Access AOD-9604 Legally in California: Step-by-Step

Given the framework above, there is one legally coherent path to AOD-9604 access in California for a patient who wants it for a clinical purpose: a valid prescription from a licensed California practitioner, fulfilled by a licensed California 503A compounding pharmacy.

Step 1. Establish Care With a Licensed Prescriber

A California-licensed MD, DO, NP, or PA must evaluate you, document a clinical rationale for the prescription, and determine that compounded AOD-9604 is appropriate for your situation. Under California telehealth law (California Business and Professions Code Section 2290.5), a synchronous audio-video visit satisfies the requirement for establishing a valid patient-prescriber relationship. [6] A prescription issued purely on the basis of an asynchronous questionnaire, without a real-time clinical evaluation, does not meet California standard of care and may not be honored by a reputable pharmacy.

Ask the prescriber directly:

• Which 503A pharmacy do they work with?
• Has that pharmacy obtained a current certificate of analysis (COA) from the bulk peptide supplier?
• What is the beyond-use date on the preparation?

Step 2. Verify the Pharmacy's License

Look up the pharmacy on the California State Board of Pharmacy license verification tool. Confirm it holds an active sterile compounding license, not merely a non-sterile compounding license. AOD-9604 is administered by subcutaneous injection, which means it must be prepared under sterile conditions consistent with USP 797. [5]

Step 3. Confirm the Preparation Specifics

A legally compounded AOD-9604 preparation for a California patient should include:

• Patient name on the label
• Prescriber name and DEA/NPI number
• Compounding pharmacy name, address, and license number
• Lot number and COA reference
• Beyond-use date (for aqueous sterile preparations, USP 797 limits BUD to 45 days refrigerated in most cases)
• "Not for resale" or "Compounded for [patient name]"

If you receive a vial without a patient-specific label, it did not come through a 503A pathway. That is a legal red flag.

Step 4. Understand the Ongoing Regulatory Risk

Because AOD-9604 remains in FDA Category 2 review, the prescriber and pharmacy are operating with uncertainty. The FDA could ultimately determine that the substance is not appropriate for compounding, which would end the 503A pathway. Patients who begin a protocol should understand that continuity of supply is not guaranteed and plan accordingly with their prescriber.

Clinical Evidence: What the Trial Data Actually Show

AOD-9604 has more clinical data behind it than most research peptides, largely because Metabolic Pharmaceuticals ran a genuine pharmaceutical development program. That program produced several trials worth examining.

Phase 2 Dose-Finding Data

A 12-week, double-blind, placebo-controlled trial in 300 obese adults tested oral AOD-9604 at doses from 1 mg to 30 mg per day. The 1 mg oral dose produced statistically significant fat mass reduction compared to placebo at 12 weeks (P<0.05), with a mean fat loss of approximately 2.8 kg in the active arm vs. 1.0 kg in the placebo arm. [2] These were oral doses, not subcutaneous, which is relevant because the injectable formulation used in current clinical practice has not been studied in the same head-to-head fashion.

Phase 3 Data and the NDA Decision

Metabolic Pharmaceuticals moved into a Phase 3 program but did not ultimately file an NDA with the FDA. The sponsor's decision not to pursue FDA approval has never been formally explained in a public document, but the absence of an NDA means there is no approved labeling, no FDA-reviewed safety database, and no standardized manufacturing requirement backed by the agency. This is a meaningful evidentiary gap. The Endocrine Society's clinical practice guidelines on obesity pharmacotherapy do not include AOD-9604 as a recommended agent. [7]

Safety Profile From Available Data

Across the Phase 2 program, adverse events were mild and comparable to placebo. No significant elevations in fasting glucose, insulin resistance, or IGF-1 were reported, which is consistent with the mechanism of action (the fragment lacks the domain that activates the GH receptor for IGF-1 production). [2] Long-term safety data beyond 12 weeks in humans do not exist in the peer-reviewed literature, which is a gap that any prescriber should disclose to patients.

A 2004 study published in the American Journal of Physiology examined the lipolytic mechanism of the hGH fragment in adipocytes and confirmed beta-3 adrenergic receptor activation as the primary pathway. [8] That mechanistic work supports the biological plausibility of the compound but does not substitute for a controlled clinical trial of the injectable formulation used in current practice.

What You Cannot Legally Do in California

Understanding prohibited conduct is as important as knowing the legal path.

Importing from overseas suppliers. The FDA enforces a strict policy against personal importation of unapproved drugs. While the agency exercises enforcement discretion in some personal-use cases, injectable peptides present a higher enforcement risk than oral supplements, and Customs and Border Protection has seized shipments of research-grade peptides at the border. Importing AOD-9604 from a Chinese or Indian bulk chemical supplier is not legal even if the quantity is for personal use.

Purchasing from "research chemical" websites. Vendors who sell AOD-9604 labeled "for research use only, not for human use" are not licensed 503A compounding pharmacies. Purchasing their product for self-administration is outside the legal compounding framework and involves accepting an unvalidated product.

Receiving a prescription from an out-of-state prescriber who has not established care. California requires that telehealth prescribers hold a valid California license when treating California patients. A prescription from an Arizona or Florida prescriber who is not licensed in California is not valid in California. [6]

How HealthRX Approaches AOD-9604 Prescribing

HealthRX physicians review each patient's medical history, metabolic labs, and body composition goals before discussing whether a compounded peptide may be appropriate. For patients interested in AOD-9604, that evaluation includes reviewing fasting insulin, HbA1c, lipid panel, and any prior weight-loss medication history. The prescriber documents clinical rationale in the chart, orders from a California-licensed 503A pharmacy with current COA documentation, and schedules a follow-up visit at 8 weeks to assess response and tolerability.

The Endocrine Society notes that "obesity is a chronic disease requiring long-term management" and that treatment decisions should be individualized based on comorbidity burden, prior treatment response, and patient preference. [7] AOD-9604 is one tool in a broader body-composition protocol that may also include dietary modification, resistance training, and, where appropriate, GLP-1 receptor agonist therapy.

Comparing AOD-9604 to FDA-Approved Alternatives

For patients considering AOD-9604 strictly for body-fat reduction, FDA-approved options exist and carry a more established evidence base.

Semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight loss at 68 weeks vs. 2.4% with placebo in the STEP-1 trial (N=1,961, P<0.001). [9] Tirzepatide 15 mg (Zepbound) produced 20.9% mean body weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539, P<0.001). [10] Neither of these agents has the legal ambiguity associated with AOD-9604.

Some patients prefer AOD-9604 because they want targeted lipolysis without the appetite-suppression side effects of GLP-1 agonists (nausea, vomiting, delayed gastric emptying). That is a clinically legitimate reason to discuss the option, but the discussion must include an honest accounting of the thinner evidence base and the regulatory uncertainty.